Hematological side-effect profiles of individualized chemotherapy regimen for recurrent ovarian cancer

Anti-Cancer Drugs

Volumn 14, Issue 5, 2003, Pages 341-346

  Breidenbach, Martina ^a,c,d   Rein, Daniel T ^b   Schöndorf, Thomas ^a   Schmidt, Torsten ^a   König, Ellen ^a   Valter, Markus ^a   Kurbacher, Christian M ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Chemosensitivity testing; Chemotherapy; Hematologic side effects; Quality of life; Recurrent ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; GEMCITABINE; MITOXANTRONE; PACLITAXEL; TOPOTECAN; TREOSULFAN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MEDICAL PRACTICE; MONOTHERAPY; OVARY CARCINOMA; PRIORITY JOURNAL; RECURRENT DISEASE; STATISTICAL ANALYSIS; THROMBOCYTOPENIA;

ADENOSINE TRIPHOSPHATE; ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LEUKOPENIA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 0038178872     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200306000-00003     Document Type: Article

References (30)

1. Alberts DS. Treatment of refractory and recurrent ovarian cancer. Semin Oncol 1999; 26:8-14.
2. Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2001; 83:504-512.
3. Gadducci A, Conte P, Cianci C, Negri S, Genazzani AR. Treatment options in patients with recurrent ovarian cancer. Anticancer Res 2001; 21:3557-3564.
4. Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 2000; 5:26-35.
5. Ozols RF. Future directions in the treatment of ovarian cancer. Semin Oncol 2002; 29:32-42.
6. Trimble E, Adams J, Vena D, et al. Paclitaxel for platinum-refractory ovarian cancer: resuls from the first 1000 patients registered to NCl treatment referral center 9103. J Clin Oncol 1993; 11:2405-2410.
7. Clarke-Pearson DL, Van Le L, Iveson T, et al. A phase II study of oral Topotecan as a single agent, second-line therapy, administered for five days in patients with advanced ovarian cancer. Proc Am Soc Clin Oncol 1999; 18:368a.
8. Gropp M, Meier W, Hepp H. Treosulfan as an effective second-line chemotherapy in recurrent ovarian cancer. Gynecol Oncol 1998; 71:94.
9. Hoskins P, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994; 12:60-63.
10. Thigpen JT. Chemotherapy of advanced ovarian cancer: overview of randomized trials. Semin Oncol 2000; 27:11-16.
11. Kurbacher CM, Cree IA, Bruckner HW, et al. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs 1998; 9:51-57.
12. Andreotti PE, Cree IA, Kurbacher CM, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assays: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55:5276-5282.
13. O'Meara AT, Sevin BU. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer. Gynecol Oncol 2001; 83:334-342.
14. Cree IA, Kurbacher CM. Individualizing chemotherapy for solid tumors - is there any alternative? Anticancer Drugs 1997; 8:541-548.
15. Kurbacher CM, Bruckner HW, Cree IA, Andreotti PA, Janat MM. A prospective clinical trial on individualized chemotherapy for recurrent ovarian cancer selected by the ex vivo ATP tumor chemosensitivity assay. Proc Am Soc Clin Oncol 1999; 18:358a.
16. Kangas L, Gronroos M, Nieminen A. Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. Med Biol 1984; 62:338-343.
17. Larrison EH. Management of side effects in patients with recurrent ovarian cancer. Semin Oncol 1999; 26:15-31.
18. Markman M. Second-line treatment of ovarian cancer with single-agent gemcitabine. Semin Oncol 2002; 29:9-10.
19. Ozols RF. The role of gemcitabine in the treatment of ovarian cancer. Semin Oncol 2000; 27:40-47.
20. Hansen SW. Gemcitabine in the treatment of ovarian cancer. Int J Gynecol Cancer 2001; 11:39-41s.
21. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 19:1530-1533.
22. Thigpen T. The role of gemcitabine-based doublets in the management of ovarian carcinoma. Semin Oncol 2002; 29:11-16.
23. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15:2183-2193.
24. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996; 14:3056-3061.
25. Kudelka AP, Tresukosol D, Edwards CL, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996; 14:1552-1557.
26. Velasco A, Matilde X, Pérez Pérez M, et al. Gemcitabine and cisplatin as treatment for patients with platinum resistant ovarian cancer and as consolidation treatment for patients with residual disease after first line chemotherapy. Proc Am Soc Clin Oncol 2001; 20:182b.
27. Kunkel LM, Evans SS, Dottino PR, et al. Cisplatin (CDDP) and gemcitabine (DFDC) in relapsed ovarian cancer. Proc Am Soc Clin Oncol 1998; 17:357a.
28. Grecu OM, Kurbacher CM, Mallmann P, et al. Treosulfan and gemcitabine in heavily pretreated patients with breast and ovarian cancer: laboratory study and clinical pilot trial of the ISCO Clinical Study Group. Proc Am Soc Clin Oncol 2001; 20:2500.
29. Meden H, Wittkop Y, Kuhn W. Maintenance chemotherapy with oral Treosulfan following first-line treatment in patients with advanced ovarian cancer. Anticancer Res 1997; 17:2221-2224.
30. Nicoletto MO, Artioli G, Donach M, et al. Elderly ovarian cancer: treatment with mitoxantrone-carboplatin. Gynecol Oncol 2001; 80:221-226.